$SCLX Cashflow Statement | Understand Stock

$SCLX

$2.05 -$0.28 (12.02%) Close

$SCLX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used for operating activities:
Interest earned on investments held in Trust Account
Change in fair value of warrant liability
Loss on initial issuance of warrant liability
Change in fair value of conversion option liability
Amortization of debt discount
Transaction costs allocated to private warrants
Depreciation and amortization
Amortization of debt issuance costs and debt discount
Scilex Pharma Notes principal increase
Accrual for transaction costs related to the Business Combination
Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount
Non-cash operating lease cost
Stock-based compensation
Issuance of shares under Settlement Agreement
Fair value of Gloperba-Elyxyb RPA liability expensed
Fair value of treasury Stock expensed - Tranche B and Oramed Note
Fair value of September 2025 warrants expensed - Tranche B modification
(Gain) loss on derivative liability
Forfeitures of private warrants
Allocated expense for financial instruments at fair value
Loss on debt extinguishment, net
Goodwill impairment
Financing costs and allocated expense for financial instruments at fair value
In-process research and development expense
Transaction costs expensed related to Semnur Business Combination
Change in fair value of debt and liability instruments
Change in fair value of equity investments
Change in fair value of digital assets
Change in fair value of equity method investment, net
Realized (gain) loss on investment, net
Realized (gain) loss on digital assets, net
Realized (gain) loss on equity method investment, net
Realized Gains & Losses on Securities
Allowances for expected credit losses
Other
Changes in operating assets and liabilities:
Prepaid expenses
Accounts receivables, net
Inventory
Prepaid expenses and other
Other long-term assets
Accounts payable
Accrued Payroll
Accrued expenses
Accrued rebates and fees
Other liabilities
Related party payable
Operating lease liability
Other long-term liabilities
Net cash (used for) proceeds from operating activities

Investing activities
Investment of cash in Trust Account
Acquisition consideration paid in cash for Romeg intangible asset acquisition
Purchase of equity securities
Cash paid for in-process research and development, net
Cash paid to settle Datavault Obligation
Purchases of Bitcoin with cash
Purchase of property, plant, and equipment
Exercise of prefunded warrant
Purchase of preferred shares of Vivasor
Sale of Datavault AI Inc. shares for cash, net
Repayments on promissory note
Payment made for PA OPS investment
Vivasor Cash Acquired
Purchase of convertible promissory note from Denali
Net cash used for investing activities

Financing activities
Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement
Proceeds from issuance of Convertible Debentures
Proceeds from issuance of Revolving Facility
Proceeds from issuance of FSF Deposit
Proceeds from issuance of Tranche B Notes and purchased revenue liability
Repayment of Revolving Facility
Repayment of Oramed Note
Cash consideration paid in connection with warrant repurchase
Cash assumed in Semnur Business Combination
Repayment of Convertible Debentures
Repayment of Tranche B Notes
Payments of debt issuance costs
Disbursement of funds to Sorrento
Cash consideration paid in connection with share repurchase
Cash consideration paid in connection with the repurchase of Penny Warrants
Transaction costs paid related to the Business Combination
Payments on purchased revenue liability
Transaction costs paid in connection with share repurchase
Proceeds from the Business Combination
Common stock Denali capital acquisition
Proceeds from exercise of April 2024 RDO Warrants and December 2024 RDO Warrants
Transaction costs paid in connection with issuance of common stock and exchange of April 2024 RDO Warrants and December 2024 RDO Warrants for November 2025 Warrants
Payments for the termination of Tumim Purchase Agreement
Proceeds from issuance of Scilex-St. James Loans
Excise tax paid in connection with share repurchase
Proceeds from issuance of shares under direct offerings
Payments of direct offering issuance costs
Payments of deferred transaction costs related to Semnur Merger
Proceeds from exercise of December 2024 RDO Warrants for Common Stock
Proceeds from stock options and warrants exercised and ESPP
Proceeds from related party payable
Repayment of advances from related party
Repayment of promissory note – related party
Proceeds from convertible promissory note – related party
Proceeds from related party note payable
Proceeds from other loans
Repayment of principal on the Scilex Pharma Notes
Repayment on other loans
Payments for Vivasor debt
Payments in lieu of fractional shares for Reverse Stock Split
Net cash (used for) financing activities

Net Change in Cash
Cash – Beginning of period
Effect of exchange rate changes on cash
Net change in cash and cash equivalents
Deferred underwriting fee payable
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure:
Cash paid for interest
Non-cash investing and financing activities
Issuance of shares to B. Riley pursuant to B. Riley Purchase Agreement
Issuance costs related to direct offerings included in accrued expenses and account payables
Net liabilities assumed in Semnur Business Combination
Derecognition of Scilex's equity investment in Denali in connection with Semnur Business Combination
Exercise of December 2024 RDO Warrants in exchange for settlement of Tranche B Notes principal and interest
Purchase of equity investment in Datavault AI Inc in exchange for Bitcoin
Bitcoin acquired in exchange for shares of Semnur Stock
Additions to intangible assets included in accrued expenses
Fee Warrants issued and exercised in connection with the Commitment Letter
Settlement of FSF Deposit
Deferred transaction costs related to Semnur Merger included in accrued expenses and account payable
Conversion of Oramed Note into Tranche B Notes
Conversion of Tranche B Notes into common stock
Debt issuance costs included in accrued expenses
Placement Agent Shares and October 2024 Placement Agent Warrants
StockBlock Warrants issued in connection with the December 2024 RDO
Conversion of Convertible Debentures into common stock
Right-of-use assets obtained in exchange for operating lease liabilities with lease modification
Oramed Note issuance at fair value
Other non-cash consideration in connection with share repurchase
Datavault Licenses acquired but not yet paid
Purchase of Bitcoin in exchange for Scilex-St. James Loans
Excise tax in connection with share repurchase included in accrued expenses
Related party debt converted to equity pursuant to Debt Exchange Agreement
Deferred consideration for Romeg intangible asset acquisition
Non-cash Consideration in Semnur Acquisition
Other Loan Forgiveness
Promissory Note issued to Sorrento in exchange for the SP-104 license
Fair value adjustment to derivative liability in troubled debt restructuring
Acquisition of right-of-use asset
Non-cash distribution to Sorrento
Issuance of shares to Yorkville
Scilex Pharma Notes principal increase
Transaction costs obligation assumed by Sorrento
Purchase and exercise of prefunded warrant for Datavault shares in exchange for Bitcoin
Issuance of warrants as financing costs in connection with issuance of common stock and exchange of liability classified instruments
Vivasor debt forgiveness
Vivasor net assets consolidated
Net impact of the issuance of November 2025 Warrants and exchange of liability classified instruments

Comments